Merck's Gardasil sales plunge as weak China demand, inventory issues and softer Japan trends cloud the vaccine's overall growth outlook in 2026.
Bank of America Global Healthcare Conference 2026 May 12, 2026 4:40 PM EDTCompany ParticipantsGrant Pickering - Co-Founder, CEO ...
Vaxcyte's new pneumococcal vaccine may only have phase 1/2 results behind it, but analysts are already predicting it could be a major competitor to rival shots from Pfizer and MSD. Just-reported data ...
The phase 2 trial of the new vaccine – known as PF-07872412 or 25vPnC – revealed stronger immune responses to the serotypes ...
OPUS-2 and OPUS-3 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults Topline Safety, Tolerability and Immunogenicity Data from OPUS-1 Expected ...
As Merck considers its life after Keytruda, much will depend on the performance of a pair of respiratory products it gained in pricey buyouts designed to cushion the blow from the megablockbuster's ...
Merck topped first-quarter sales estimates as Winrevair and injectable Keytruda Qlex helped support revenue growth.
Vaxcyte is evolving from a single-product biotech into a commercial vaccine platform with advanced manufacturing and regulatory alignment. VAX-31, a 31-valent pneumococcal conjugate vaccine, targets ...
Investor's Business Daily on MSN
How S&P drug titan Pfizer plans to outdo its own $6 billion franchise
The next-generation version of Pfizer's $6 billion pneumococcal vaccine franchise topped its predecessor in a midstage study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results